ArticleComputational and structural biotechnology journal2025
Identification of shared and unique mechanisms of atopic dermatitis and ulcerative colitis by construction and computational analysis of disease maps.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evolving Research Hotspots and Emerging Trends in Atopic Dermatitis and Inflammatory Bowel Disease: A Bibliometric Analysis.Clinical, cosmetic and investigational dermatology · 2026Article
- From tissue to blood: an integrated multi-omics signature identifies fibrogenesis and neutrophil activation as key drivers of ulcerative colitis severity.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) and ulcerative colitis (UC) are immune-mediated inflammatory diseases (IMIDs) with high prevalence and treatment costs. AD mainly affects the skin, while UC targets the colon and rectum, but both are characterised by immune dysregulation driven by aberrant T helper cell activation, persistent barrier dysfunction, genetic predisposition, and environmental triggers. This overlap may explain the link between the two diseases and the increased risk of UC in patients with AD. Both diseases are chronic, progressive, and limited in treatment options, and there is a need for a better understanding of their mechanisms and biomarkers. To address this, we developed disease maps for UC and AD, covering their molecular mechanisms. Here, we present the development and contents of the maps, as well as demonstrate their application in data visualisation and analysis. Our systematic, interactive comparison reveals both common and disease-specific signatures, as well as common pathological pathways. These findings highlight shared biomarkers for predicting progression and therapy outcomes, and opportunities for drug repurposing. The UC and AD disease maps provide a valuable resource for representing and exploring common and distinct mechanisms, helping to advance IMID management from organ-based symptom relief towards mechanism-based treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.